NCT05683691进行中（未招募）不适用
Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR
Francis Medical Inc.26 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2023年5月16日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
- 试验地点
- 26
- 主要终点
- Primary Safety Endpoint
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •≥50 years of age; with life expectancy of ≥10 years
- •20-80 cc prostate size determined by MRI Central Imaging
- •≤15 ng/ml PSA
- •Cancer stage less than or equal to T2c
- •Within 12 months prior to signing consent have had a multiparametric MRI. Within 6 months prior to signing consent, have undergone a multiparametric MRI software guided fusion biopsy of the prostate (transrectal or transperineal). This must include a standard sector biopsy obtaining a minimum of 10 cores.
- •<15mm diameter of qualifying lesion as measure by greatest diameter
- •Subject is willing and able to adhere to specific protocol visits and required testing throughout study
- •Is geographically stable and near the site or able and willing to travel back to site for follow-up visits involving diagnostic tests or treatment
- •Able and willing to provide written consent to participate in the study.
- •Subject is willing and able to be treated within 180 days after signing consent.
排除标准
- •Patients with >GGG3 cores anywhere in the prostate
- •MRI evidence of extracapsular extension of cancer (MRI read as "definite", "frank" or "gross" ECE)
- •All MRI Central Imaging confirmed PI-RADS 5 lesions
- •All MRI Central Imaging confirmed additional PI-RADS 4 lesions.
- •Contraindications to MRI
- •Subjects with an installed pacemaker or other potentially electrically conductive implants implanted within 200mm (8 inches) of the procedure area. Implants that are within 200mm (8 inches) and can be turned off for the duration of the study procedure are acceptable.
- •Any prior surgery, intervention, or minimally invasive therapy, (MIST) for the prostate cancer or bladder neck.
- •Treated within the past 5 years for genital cancer
- •Presence of any urethral or prostatic condition that precludes water vapor ablation per Instructions for Use
- •Currently taking medications that have hormonal effects on the prostate or PSA, such as: 5 alpha reductase inhibitors (if on for <6 months, 6-month washout), Androgen blockers, Luteinizing hormone-releasing hormone (LHRH) agonists or antagonists (12-month washout), or Testosterone supplementation (3-month washout)
- •Active urinary tract infection. Subjects with an active infection who can be treated and re-tested with a negative result within the screening window are acceptable.
- •Active or clinically chronic prostatitis or granulomatous prostatitis
- •Treated within the past 5 years for a lower and/or upper urinary tract malignancy.
- •Any previous treatment for prostate cancer.
- •Any rectal pathology, anomaly or previous treatment that could change properties of rectal wall or insertion and use of TRUS
- •Unable to stop taking antiplatelet medications or other blood thinning agents
- •Known allergy to nickel
- •Allergic to medication required by the study such as MRI contrast or anesthesia
- •Any significant medical history that would pose an unreasonable risk or make the subject unsuitable for the study
- •Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study Investigator regarding the study or affects the ability to complete the study quality of life questionnaires
- •Subject currently participating in other premarket investigational studies unless approved by Sponsor in writing
- •Subject is considered vulnerable such as incarcerated or cognitively impaired.
研究组 & 干预措施
Vanquish System Treatment
Experimental
干预措施: Vanquish System (Device)
结局指标
主要结局
Primary Safety Endpoint
时间窗: 12 months
The proportion of subjects free from new or worsening urinary incontinence based on pad use at 12 months will be statistically compared to a performance goal.
Primary Effectiveness Endpoint
时间窗: 36 months
Freedom from systemic disease AND systemic therapy AND salvage therapy AND GGG≥2.
次要结局
- Key Secondary Endpoint(36 months)
研究者
研究点 (26)
Loading locations...
相似试验
尚未招募
4 期
Vunakizumab in Adults with SpondyloarthritisSpondyloarthritis (SpA)NCT06770088Sun Yat-sen University880
Enrolling By Invitation
2 期
A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLCNon-small Cell Lung CancerNCT05360979Second Xiangya Hospital of Central South University42
已完成
4 期
Prevena Spine for Use in Spine SurgerySurgeryIncision, SurgicalNCT05555355Northwestern University104
已完成
不适用
VIRTUS: An Evaluation of the Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow ObstructionChronic Venous DisorderVenous Outflow ObstructionSymptomatic Venous Outflow Obstruction of Iliofemoral VeinNCT02112877Boston Scientific Corporation200
招募中
不适用
Observational study on efficacy and safety of vaccines against the novel coronavirus disease (COVID-19) in hematopoietic stem cell transplantation (HSCT) patient.allo-SCTJPRN-UMIN000043671Fukuoka Blood and Marrow Transplantation Group1,000